
    
      All patients received cetuximab: 400 mg/m2 (first cycle only) administered intravenously (IV)
      on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8.
      Day 1 cetuximab was immediately followed by bevacizumab 5 mg/kg IV, oxaliplatin 85 mg/m2 IV,
      and 5-fluorouracil 400 mg/m2 IV bolus, followed by 2400 mg/m2 administered as a continuous
      infusion over 46 hours via a pump (outpatient) and leucovorin 350 mg IV (modified FOLFOX6).
      Cycles were 14 days.
    
  